Loading…
Employees: 130
Size SEERS (458870.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $409M, the 386th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩14,500 on 6 Nov 2026.
Performance Over six months the shares fell 69.6%, against -20.2% for the median peer and -24.5% for the South Korea market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue grew 424.8% over the last twelve months (peer median +6.8%); the operating margin is 43.4% (peer median 4.7%).
Valuation It trades at 10.1× forward earnings against a peer median of 20.8× (3rd cheapest of 9).
Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +247%, so the hurdle is -256 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 59.6 points above its cost of capital (5.5% WACC).
Next results Next results expected around 13 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩97.0B | ₩48.2B | ₩8.10B | ₩1.89B | ₩1.15B |
| Revenue growth | — | +495% | +330% | +63% | — |
| Gross profit | ₩66.6B | ₩34.2B | ₩2.86B | -₩1.30B | -₩829M |
| EBITDA | ₩43.7B | ₩17.6B | -₩7.56B | -₩8.81B | -₩7.48B |
| Net income | ₩41.9B | ₩16.1B | -₩8.87B | -₩9.92B | -₩7.99B |
| Free cash flow | ₩15.6B | ₩610M | -₩11.5B | -₩8.58B | -₩17.3B |
| Capital expenditure | ₩3.16B | ₩2.13B | ₩1.41B | ₩1.11B | ₩8.91B |
| Total debt | ₩5.21B | ₩3.81B | ₩3.05B | ₩6.29B | ₩1.72B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 458870.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -44.2% | -11.3% | lowest of 21 |
| 6-month return | -69.6% | -20.2% | lowest of 20 |
| Distance from 52-week high | -77.4% | -40.2% | 2nd lowest of 21 |
| Revenue growth (TTM) | +424.8% | +6.8% | highest of 20 |
| Operating margin | 43.4% | 4.7% | highest of 20 |
| Forward P/E | 10.1× | 20.8× | 3rd cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | -9.1% | 11.8% | 2nd least demanding of 10 |
| Growth delivered (Del g) | +247.0% | +4.4% | highest of 10 |
| Hurdle (Req g minus delivered) | -256.1 pp | +6.2 pp | least demanding of 10 |
| ROIC minus cost of capital | +59.6 pp | -5.9 pp | highest of 19 |
| EV / EBITDA | 12.3× | 16.5× | 3rd cheapest of 6 |
| Net debt / EBITDA | -0.5× | -2.1× | 3rd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SEERS 458870.KS | South Korea | $409M | -70% | +425% | 43% | 10.1× | -9.1% | +247.0% |
| Beijing Succeeder Technology 688338.SS | China | $408M | -15% | -4% | 31% | 18.4× | 9.8% | +3.4% |
| Cerus CERS | United States | $408M | -23% | +14% | -12% | n/a | n/a | n/a |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $412M | n/a | +19% | 3% | n/a | 23.3% | +18.1% |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $407M | -14% | +3% | -45% | n/a | n/a | n/a |
| Ningbo Tianyi Medical Appliance 301097.SZ | China | $407M | -20% | +46% | 8% | n/a | n/a | n/a |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $406M | -13% | +7% | 11% | 27.5× | -2.5% | -6.0% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $417M | +3% | +12% | 6% | 40.9× | 55.5% | +3.8% |
| YD Bio YDES | United States | $423M | -58% | +17% | -883% | n/a | n/a | n/a |
| SS Innovations International SSII | United States | $423M | -45% | +90% | -16% | n/a | n/a | n/a |
| Taidoc Technology 4736.TW | Taiwan | $395M | 0% | -6% | 18% | n/a | -8.0% | -6.6% |
| Shoulder Innovations SI | United States | $428M | +56% | +61% | -59% | n/a | n/a | n/a |
| NeuroPace NPCE | United States | $429M | -32% | +12% | -15% | n/a | n/a | n/a |
| OrbusNeich Medical 6929.HK | Hong Kong | $389M | -3% | +16% | 23% | 8.3× | -18.5% | +15.4% |
| Shanghai Titan Scientific 688133.SS | China | $432M | -22% | -5% | -5% | 9.0× | n/a | n/a |
| Clarity Pharmaceuticals CU6.AX | Australia | $386M | -48% | n/a | n/a | n/a | n/a | n/a |
| Nanjing Medlander Medical Technology 688273.SS | China | $385M | -44% | -12% | 8% | 20.0× | 39.0% | +5.2% |
| 908 Devices MASS | United States | $436M | +29% | +1% | -35% | n/a | n/a | n/a |
| Guanhao Biotech 300238.SZ | China | $440M | -25% | -7% | 5% | n/a | n/a | n/a |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $380M | -23% | -8% | 17% | 38.5× | 20.0% | +4.4% |
| Chison Medical Technologies 688358.SS | China | $443M | -16% | -1% | 19% | 21.6× | 11.8% | +5.6% |